Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
MILLBRAE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. NASDAQ:EIKN (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported third quarter 2026 financial results and provided upd…